Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Fig. 1

Liver to body weight ratio (a) and liver triglyceride content (b) in the five groups. Data are mean ± SE. *P < 0.05, †P < 0.01, ‡P < 0.001 vs. control; §P < 0.05, ||P < 0.01, ¶P < 0.001 vs. vehicle; #P < 0.05 vs. Linagliptin alone

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us